{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. In addition, we will review all toxicities data that is graded as 3, 4, or 5 and classified as either \"unrelated or unlikely to be related\" to study treatment in the event of an actual relationship developing. Adverse events and toxicities will be evaluated using all patients who have received any study treatment.","groups":[{"description":"Patients receive obatoclax mesylate IV over 3 hours and bortezomib (1.3 mg/m\\^2) IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"populationDescription":"No participants proceeded to Phase II for evaluation.","reportingStatus":"POSTED","timeFrame":"From baseline to up to 3 years","title":"Toxicity as Assessed by the National Cancer Institute (NCI) CTCAE v 3.0 (Phase II)","type":"SECONDARY"}